Analysts have been eager to weigh in on the Healthcare sector with new ratings on Aclaris Therapeutics Inc (ACRS), Merck & Company (MRK) and BioDelivery (BDSI).
Aclaris Therapeutics Inc (ACRS)
In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Aclaris Therapeutics Inc, with a price target of $50. The company’s shares closed yesterday at $6.97, close to its 52-week low of $5.95.
Chen observed:
“We expect upwards earnings revisions to levels not reflected in sell-side consensus expectations to drive shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $50.”
According to TipRanks.com, Chen is a 4-star analyst with an average return of 7.0% and a 37.6% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Amneal Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.
Currently, the analyst consensus on Aclaris Therapeutics Inc is a Moderate Buy with an average price target of $50.
See today’s analyst top recommended stocks >>
Merck & Company (MRK)
In a report released today, Alex Arfaei from BMO Capital maintained a Hold rating on Merck & Company, with a price target of $80. The company’s shares closed yesterday at $74.43.
According to TipRanks.com, Arfaei is a 5-star analyst with an average return of 8.6% and a 70.6% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Elanco Animal Health Inc, Eli Lilly & Co, and Bristol Myers.
Currently, the analyst consensus on Merck & Company is a Strong Buy with an average price target of $82.20.
BioDelivery (BDSI)
Cantor Fitzgerald analyst Brandon Folkes maintained a Buy rating on BioDelivery today and set a price target of $5. The company’s shares closed yesterday at $4.62, close to its 52-week high of $4.65.
Folkes observed:
“We view BDSI as a Belbuca execution story, and, based on Symphony script data, the company is exceeding its execution goals as well as our expectations. Execution, as well as increased access for Belbuca going into 2019 have increased our conviction that solid execution in 2019 and beyond is likely to continue, which should drive upward earnings revisions and further upside in BDSI stock. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to reach our 12-month price target of $5.00.”
According to TipRanks.com, Folkes is a 1-star analyst with an average return of -2.0% and a 40.3% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Opiant Pharmaceuticals Inc, Collegium Pharmaceutical, and ANI Pharmaceuticals Inc.
BioDelivery has an analyst consensus of Strong Buy, with a price target consensus of $5, an 8.2% upside from current levels. In a report released yesterday, Janney Montgomery also initiated coverage with a Buy rating on the stock with a $5 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
